Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03831932
Title	Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	National Cancer Institute (NCI)
Indications	lung non-small cell carcinoma
Therapies	Osimertinib + Telaglenastat
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
University of Alabama at Birmingham Cancer Center	Active, not recruiting	Birmingham	Alabama	35233	United States	Details
UM Sylvester Comprehensive Cancer Center at Coral Gables	Recruiting	Coral Gables	Florida	33146	United States	Details
UM Sylvester Comprehensive Cancer Center at Deerfield Beach	Recruiting	Deerfield Beach	Florida	33442	United States	Details
University of Miami Miller School of Medicine-Sylvester Cancer Center	Recruiting	Miami	Florida	33136	United States	Details
UM Sylvester Comprehensive Cancer Center at Plantation	Recruiting	Plantation	Florida	33324	United States	Details
University of Kentucky/Markey Cancer Center	Recruiting	Lexington	Kentucky	40536	United States	Details
Case Western Reserve University	Recruiting	Cleveland	Ohio	44106	United States	Details
Ohio State University Comprehensive Cancer Center	Recruiting	Columbus	Ohio	43210	United States	Details
University of Pittsburgh Cancer Institute (UPCI)	Recruiting	Pittsburgh	Pennsylvania	15232	United States	Details
Huntsman Cancer Institute/University of Utah	Recruiting	Salt Lake City	Utah	84112	United States	Details
University of Virginia Cancer Center	Recruiting	Charlottesville	Virginia	22908	United States	Details

*Shaded cells indicate that there was no data available from clincialtrials.gov for the field